Alder Biopharmaceuticals Inc (ALDR) 25.13 $ALDR
Why You Shouldn't Bet Against Alder Biopharmaceuticals (ALDR) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 7:56AM CDT
Alder Biopharmaceuticals is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 45
ALDR: 25.13 (-0.19)
Teva migraine drug successful
at Investor's Business Daily - Mon Mar 23, 6:04PM CDT
The Israeli pharmaceutical giant reported successful phase 2b study results of TEV-48125, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treating episodic migraines. Teva Pharmaceutical Industries (TEVA) shares rose 0.9% to 62.65,...
ALDR: 25.13 (-0.19), LLY: 72.30 (+0.09), TEVA: 63.01 (-1.15)
Teva Migraine Drug Scores In Race With Alder, Lilly
at Investor's Business Daily - Mon Mar 23, 12:18PM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported successful midstage trial results for its novel migraine treatment and appointed a new head of business development Monday, sending its stock to a five-year high above 63. Teva...
ALDR: 25.13 (-0.19), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), TEVA: 63.01 (-1.15)
Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth
M2 - Mon Mar 23, 11:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf5t6/rheumatoid) has announced the addition of the "Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth" report to their offering. Modest Rate of Market Growth Expected between 2013 and 2020 The market for disease-modifying RA therapeutics is expected to increase from $56.6 billion in 2013 to $80.7 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 5.2%. First-line DMARDs are expected to remain stagnant, as the late-stage pipeline predominantly constitutes second-line therapies. The high number of clinically and commercially strong products in the current market represents a barrier for the market infiltration of such emerging therapies. In the EU market, the patent expiration of blockbuster drugs from 2015 is expected to cause a strong uptake of biosimilars. However, uncertainty over the regulatory guidelines that govern the approval pathway of biosimilars into the US, the largest RA market across the eight key territories, may not measurably affect the pricing of the currently marketed drugs. Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Disease Introduction 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Epidemiology 2.7 Co-morbidities and Complications 2.8 Disease Progression 2.9 Pharmacotherapy Algorithm 2.10 Treatment Options 2.10.1 Pharmacological 2.10.2 Methotrexate 2.10.3 Plaquenil (hydroxychloroquine) 2.10.4 Arava (leflunomide) 2.10.5 Azulfidine, Salazopyrin (sulfasalazine) 2.10.6 Neoral (cyclosporine) 2.10.7 Prograf (tacrolimus) 2.10.8 Xeljanz (tofacitinib) 2.11 Other Non-biologics 2.12 Biologic Disease-Modifying Anti-rheumatic Drugs 2.12.1 Tumor Necrosis Factor Alpha Inhibitors 2.12.2 Interleukin Inhibitors 2.12.3 Other Biologics that Target B- and T-Cell Antigens 2.13 Disease Scoring Methods for Measuring Treatment Efficacy 3 Marketed Products 3.1 Overview 3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 3.2.1 Methotrexate-Based Products 3.2.2 Xeljanz (tofacitinib) - Pfizer 3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 3.3.1 Remicade (infliximab) - Johnson and Johnson, Merck 3.3.2 Remsima - infliximab biosimilar 3.3.3 Humira (adalimumab) - Abbvie 3.3.4 Enbrel (etanercept) - Amgen, Pfizer and Takeda Pharmaceutical 3.3.5 Rituxan (rituximab) - Genentech (Roche), Biogen IDEC 3.3.6 Reditux (Non-comparable Biologic of Rituxan) 3.3.7 AcellBia (rituximab biosimilar) 3.3.8 Orencia (abatacept) - Bristol-Myers Squibb 3.3.9 Simponi (golimumab) - Johnson and Johnson, Merck 3.3.10 Cimzia (certolizumab pegol) - UCB 3.3.11 Kineret (anakinra) - Swedish Orphan Biovitrum 3.3.12 Actemra (tocilizumab) - Roche 3.3.13 Comparative Safety and Efficacy 3.4 Unmet Need 4 Pipeline Landscape 5 Clinical Trial Analysis 6 Market Forecasts to 2020 7 Deals and Strategic Consolidations 7.1 Licensing agreements 7.1.1 Deal Values by Therapeutic Molecule Types 7.1.2 Deal Values by Therapeutic mechanism of administration 7.1.3 AstraZeneca Enters into Licensing Agreement with Rigel Pharma for fostamatinib disodium 7.1.4 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb Company Alder Biopharmaceuticals for Clazakizumab 7.1.5 Janssen Biotech enters into a licensing deal with Astellas Pharma for Peficitinib 7.1.6 Ablynx enters into a licensing deal with Abbvie for the Nanobody ALX-006 7.2 Co-development 7.2.1 Deal Values by Therapeutic Molecule Types and Phase 7.2.2 Deal Values by Therapeutic mechanism of administration and Phase 7.2.3 GlaxoSmithKline enters into Global Agreement with Archemix 7.2.4 Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib 7.2.5 Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline 8 Appendix For more information visit http://www.researchandmarkets.com/research/grf5t6/rheumatoid
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), ABT: 48.35 (+1.23), ALDR: 25.13 (-0.19), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21)
Research and Markets: Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023
Business Wire - Wed Mar 18, 1:30PM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mt7q8/clazakizumab) has announced the addition of the "Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.
ALDR: 25.13 (-0.19)
Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023
M2 - Wed Mar 18, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/39gwd9/clazakizumab) has announced the addition of the "Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Clazakizumab is a humanized mAb directed against IL-6 that is in Phase IIb of development by Alder Biopharmaceuticals for the treatment of moderate to severe RA. It is expected to be used as an SC injection, in combination with MTX, but is also under investigation for use as a monotherapy. Clazakizumab blocks IL-6 and therefore reduces inflammation, as well as swelling, pain, and joint destruction, associated with RA. Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Clazakizumab including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Clazakizumab for the top seven countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines 4.1.3 Leading Prescribed Drugs for the Treatment of RA 4.1.4 Clinical Practice 5 Competitive Assessment 6 Unmet Need and Opportunity 6.1 Overview 6.2 Development of Cost-Effective Therapies 6.3 Biomarkers to Predict Responsiveness to Therapy 6.4 Early Diagnosis of RA 6.5 Personalized Treatment Approach 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 8 Clazakizumab 9 Appendix For more information visit http://www.researchandmarkets.com/research/39...azakizumab
ALDR: 25.13 (-0.19)
Alder's (ALDR) CEO Randy Schatzman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 6:22PM CST
ALDR: 25.13 (-0.19)
Alder Bio misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:04PM CST
ALDR: 25.13 (-0.19)
Alder Bio reports after the close
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 12:30PM CST
ALDR: 25.13 (-0.19)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.36), GPRO: 46.25 (+1.94), CLDN: 13.59 (-2.77), ZEN: 23.61 (-0.19), ASPX: 100.79 (+0.09), TNET: 35.45 (-0.54), NVRO: 53.50 (+0.53), OCUL: 25.90 (-0.05), RDUS: 41.90 (-0.48), ALDR: 25.13 (-0.19), IRMD: 15.70 (+0.03), KITE: 57.56 (-1.43), TUBE: 15.54 (+0.04), VBLT: 4.37 (-0.08)
Alder BioPharmaceuticals to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 7:07AM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will discuss Alder in a fireside chat at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 10:20 a.m. EST in New York, NY.
ALDR: 25.13 (-0.19)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 25.13 (-0.19), ALDX: 9.30 (-1.45), ADHD: 5.82 (+0.12), ALXN: 188.19 (+1.41), ALXA: 2.01 (-0.01)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 5.18 (+0.14), RNST: 30.61 (+0.10), ASPX: 100.79 (+0.09), FDO: 79.25 (-0.09), SHLD: 42.16 (+0.39), SNI: 69.88 (+1.13), ADBE: 75.50 (+0.88), VSTM: 9.99 (unch), ALDR: 25.13 (-0.19), ALNY: 118.00 (-2.70), SSP: 23.52 (+0.13), SGNT: 25.43 (-0.29), MA: 91.20 (+3.43), WIA: 11.60 (-0.04), CRM: 67.71 (+0.33), SCHW: 30.46 (+0.30)
Alder BioPharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares
GlobeNewswire - Thu Jan 22, 3:02PM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 900,000 shares of common stock. The closing of the option exercise occurred on January 22, 2015. Gross proceeds from the offering of an aggregate of 6,900,000 shares at a public offering price of $29.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $203.6 million.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 25.13 (-0.19), PRXL: 67.12 (-0.42), ILMN: 190.04 (-9.27), AGIO: 103.51 (-4.12), PRAH: 27.90 (+0.42), BMY: 66.60 (-0.21), ICLR: 69.24 (+1.28)
Alder Bio prices offering
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:51PM CST
ALDR: 25.13 (-0.19)
Alder BioPharmaceuticals Announces Pricing of Follow-On Offering
GlobeNewswire - Thu Jan 08, 8:19AM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $29.50 per share. Alder is offering all of the shares of common stock. In addition, Alder has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price. The offering is expected to close on January 13, 2015, subject to customary closing conditions.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
Alder Bio commences secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:15PM CST
ALDR: 25.13 (-0.19)
Alder BioPharmaceuticals Announces Commencement of Follow-On Offering
GlobeNewswire - Mon Jan 05, 3:39PM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today that it has commenced a public offering of 4,000,000 shares of its common stock. Alder is offering all of the shares of common stock. In addition, Alder expects to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis
PR Newswire - Mon Dec 29, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alder (NASDAQ: ALDR), Sky Solar (NASDAQ: SKYS), CNinsure (NASDAQ: CISG), Raytheon (NYSE: RTN), and Actavis (NYSE: ACT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ACT: 295.22 (+0.69), ALDR: 25.13 (-0.19), RTN: 109.65 (+0.82), SKYS: 10.98 (+0.08), CISG: 9.82 (-0.17)
Why You Shouldn't Bet Against Alder Biopharmaceuticals (ALDR) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 7:56AM CDT
Alder Biopharmaceuticals is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 45
ALDR: 25.13 (-0.19)
Teva migraine drug successful
at Investor's Business Daily - Mon Mar 23, 6:04PM CDT
The Israeli pharmaceutical giant reported successful phase 2b study results of TEV-48125, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treating episodic migraines. Teva Pharmaceutical Industries (TEVA) shares rose 0.9% to 62.65,...
ALDR: 25.13 (-0.19), LLY: 72.30 (+0.09), TEVA: 63.01 (-1.15)
Teva Migraine Drug Scores In Race With Alder, Lilly
at Investor's Business Daily - Mon Mar 23, 12:18PM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported successful midstage trial results for its novel migraine treatment and appointed a new head of business development Monday, sending its stock to a five-year high above 63. Teva...
ALDR: 25.13 (-0.19), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), TEVA: 63.01 (-1.15)
Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth
M2 - Mon Mar 23, 11:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grf5t6/rheumatoid) has announced the addition of the "Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth" report to their offering. Modest Rate of Market Growth Expected between 2013 and 2020 The market for disease-modifying RA therapeutics is expected to increase from $56.6 billion in 2013 to $80.7 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 5.2%. First-line DMARDs are expected to remain stagnant, as the late-stage pipeline predominantly constitutes second-line therapies. The high number of clinically and commercially strong products in the current market represents a barrier for the market infiltration of such emerging therapies. In the EU market, the patent expiration of blockbuster drugs from 2015 is expected to cause a strong uptake of biosimilars. However, uncertainty over the regulatory guidelines that govern the approval pathway of biosimilars into the US, the largest RA market across the eight key territories, may not measurably affect the pricing of the currently marketed drugs. Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Disease Introduction 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Epidemiology 2.7 Co-morbidities and Complications 2.8 Disease Progression 2.9 Pharmacotherapy Algorithm 2.10 Treatment Options 2.10.1 Pharmacological 2.10.2 Methotrexate 2.10.3 Plaquenil (hydroxychloroquine) 2.10.4 Arava (leflunomide) 2.10.5 Azulfidine, Salazopyrin (sulfasalazine) 2.10.6 Neoral (cyclosporine) 2.10.7 Prograf (tacrolimus) 2.10.8 Xeljanz (tofacitinib) 2.11 Other Non-biologics 2.12 Biologic Disease-Modifying Anti-rheumatic Drugs 2.12.1 Tumor Necrosis Factor Alpha Inhibitors 2.12.2 Interleukin Inhibitors 2.12.3 Other Biologics that Target B- and T-Cell Antigens 2.13 Disease Scoring Methods for Measuring Treatment Efficacy 3 Marketed Products 3.1 Overview 3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 3.2.1 Methotrexate-Based Products 3.2.2 Xeljanz (tofacitinib) - Pfizer 3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 3.3.1 Remicade (infliximab) - Johnson and Johnson, Merck 3.3.2 Remsima - infliximab biosimilar 3.3.3 Humira (adalimumab) - Abbvie 3.3.4 Enbrel (etanercept) - Amgen, Pfizer and Takeda Pharmaceutical 3.3.5 Rituxan (rituximab) - Genentech (Roche), Biogen IDEC 3.3.6 Reditux (Non-comparable Biologic of Rituxan) 3.3.7 AcellBia (rituximab biosimilar) 3.3.8 Orencia (abatacept) - Bristol-Myers Squibb 3.3.9 Simponi (golimumab) - Johnson and Johnson, Merck 3.3.10 Cimzia (certolizumab pegol) - UCB 3.3.11 Kineret (anakinra) - Swedish Orphan Biovitrum 3.3.12 Actemra (tocilizumab) - Roche 3.3.13 Comparative Safety and Efficacy 3.4 Unmet Need 4 Pipeline Landscape 5 Clinical Trial Analysis 6 Market Forecasts to 2020 7 Deals and Strategic Consolidations 7.1 Licensing agreements 7.1.1 Deal Values by Therapeutic Molecule Types 7.1.2 Deal Values by Therapeutic mechanism of administration 7.1.3 AstraZeneca Enters into Licensing Agreement with Rigel Pharma for fostamatinib disodium 7.1.4 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb Company Alder Biopharmaceuticals for Clazakizumab 7.1.5 Janssen Biotech enters into a licensing deal with Astellas Pharma for Peficitinib 7.1.6 Ablynx enters into a licensing deal with Abbvie for the Nanobody ALX-006 7.2 Co-development 7.2.1 Deal Values by Therapeutic Molecule Types and Phase 7.2.2 Deal Values by Therapeutic mechanism of administration and Phase 7.2.3 GlaxoSmithKline enters into Global Agreement with Archemix 7.2.4 Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib 7.2.5 Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline 8 Appendix For more information visit http://www.researchandmarkets.com/research/grf5t6/rheumatoid
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), ABT: 48.35 (+1.23), ALDR: 25.13 (-0.19), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21)
Research and Markets: Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023
Business Wire - Wed Mar 18, 1:30PM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mt7q8/clazakizumab) has announced the addition of the "Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.
ALDR: 25.13 (-0.19)
Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023
M2 - Wed Mar 18, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/39gwd9/clazakizumab) has announced the addition of the "Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Clazakizumab is a humanized mAb directed against IL-6 that is in Phase IIb of development by Alder Biopharmaceuticals for the treatment of moderate to severe RA. It is expected to be used as an SC injection, in combination with MTX, but is also under investigation for use as a monotherapy. Clazakizumab blocks IL-6 and therefore reduces inflammation, as well as swelling, pain, and joint destruction, associated with RA. Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Clazakizumab including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Clazakizumab for the top seven countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines 4.1.3 Leading Prescribed Drugs for the Treatment of RA 4.1.4 Clinical Practice 5 Competitive Assessment 6 Unmet Need and Opportunity 6.1 Overview 6.2 Development of Cost-Effective Therapies 6.3 Biomarkers to Predict Responsiveness to Therapy 6.4 Early Diagnosis of RA 6.5 Personalized Treatment Approach 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 8 Clazakizumab 9 Appendix For more information visit http://www.researchandmarkets.com/research/39...azakizumab
ALDR: 25.13 (-0.19)
Alder's (ALDR) CEO Randy Schatzman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 6:22PM CST
ALDR: 25.13 (-0.19)
Alder Bio misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:04PM CST
ALDR: 25.13 (-0.19)
Alder Bio reports after the close
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 12:30PM CST
ALDR: 25.13 (-0.19)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.36), GPRO: 46.25 (+1.94), CLDN: 13.59 (-2.77), ZEN: 23.61 (-0.19), ASPX: 100.79 (+0.09), TNET: 35.45 (-0.54), NVRO: 53.50 (+0.53), OCUL: 25.90 (-0.05), RDUS: 41.90 (-0.48), ALDR: 25.13 (-0.19), IRMD: 15.70 (+0.03), KITE: 57.56 (-1.43), TUBE: 15.54 (+0.04), VBLT: 4.37 (-0.08)
Alder BioPharmaceuticals to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 7:07AM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will discuss Alder in a fireside chat at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 10:20 a.m. EST in New York, NY.
ALDR: 25.13 (-0.19)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 25.13 (-0.19), ALDX: 9.30 (-1.45), ADHD: 5.82 (+0.12), ALXN: 188.19 (+1.41), ALXA: 2.01 (-0.01)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 5.18 (+0.14), RNST: 30.61 (+0.10), ASPX: 100.79 (+0.09), FDO: 79.25 (-0.09), SHLD: 42.16 (+0.39), SNI: 69.88 (+1.13), ADBE: 75.50 (+0.88), VSTM: 9.99 (unch), ALDR: 25.13 (-0.19), ALNY: 118.00 (-2.70), SSP: 23.52 (+0.13), SGNT: 25.43 (-0.29), MA: 91.20 (+3.43), WIA: 11.60 (-0.04), CRM: 67.71 (+0.33), SCHW: 30.46 (+0.30)
Alder BioPharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares
GlobeNewswire - Thu Jan 22, 3:02PM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 900,000 shares of common stock. The closing of the option exercise occurred on January 22, 2015. Gross proceeds from the offering of an aggregate of 6,900,000 shares at a public offering price of $29.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $203.6 million.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 25.13 (-0.19), PRXL: 67.12 (-0.42), ILMN: 190.04 (-9.27), AGIO: 103.51 (-4.12), PRAH: 27.90 (+0.42), BMY: 66.60 (-0.21), ICLR: 69.24 (+1.28)
Alder Bio prices offering
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:51PM CST
ALDR: 25.13 (-0.19)
Alder BioPharmaceuticals Announces Pricing of Follow-On Offering
GlobeNewswire - Thu Jan 08, 8:19AM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $29.50 per share. Alder is offering all of the shares of common stock. In addition, Alder has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price. The offering is expected to close on January 13, 2015, subject to customary closing conditions.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
Alder Bio commences secondary offering
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:15PM CST
ALDR: 25.13 (-0.19)
Alder BioPharmaceuticals Announces Commencement of Follow-On Offering
GlobeNewswire - Mon Jan 05, 3:39PM CST
Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today that it has commenced a public offering of 4,000,000 shares of its common stock. Alder is offering all of the shares of common stock. In addition, Alder expects to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price.
ALDR: 25.13 (-0.19), WFC: 54.67 (+0.39)
Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis
PR Newswire - Mon Dec 29, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alder (NASDAQ: ALDR), Sky Solar (NASDAQ: SKYS), CNinsure (NASDAQ: CISG), Raytheon (NYSE: RTN), and Actavis (NYSE: ACT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ACT: 295.22 (+0.69), ALDR: 25.13 (-0.19), RTN: 109.65 (+0.82), SKYS: 10.98 (+0.08), CISG: 9.82 (-0.17)
